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Abstract
Background: Usher syndrome (USH) is an autosomal recessive disorder characterized by hearing impairment and
vision dysfunction due to retinitis pigmentosa. Phenotypic and genetic heterogeneities of this disease make it
impractical to obtain a genetic diagnosis by conventional Sanger sequencing.
Methods: In this study, we applied a next-generation sequencing approach to detect genetic abnormalities in
patients with USH. Two unrelated Chinese families were recruited, consisting of two USH afflicted patients and
four unaffected relatives. We selected 199 genes related to inherited retinal diseases as targets for deep exome
sequencing. Through systematic data analysis using an established bioinformatics pipeline, all variants that passed
filter criteria were validated by Sanger sequencing and co-segregation analysis.
Results: A homozygous frameshift mutation (c.4382delA, p.T1462Lfs*2) was revealed in exon20 of gene USH2A
in the F1 family. Two compound heterozygous mutations, IVS47 + 1G > A and c.13156A > T (p.I4386F), located in
intron 48 and exon 63 respectively, of USH2A, were identified as causative mutations for the F2 family. Of note, the
missense mutation c.13156A > T has not been reported so far.
Conclusion: In conclusion, targeted exome sequencing precisely and rapidly identified the genetic defects in
two Chinese USH families and this technique can be applied as a routine examination for these disorders with
significant clinical and genetic heterogeneity.
Background
Usher syndrome (USH) is the most prevalent cause of
hereditary deafness-blindness in humans [1]. It occurs
in approximately 1 of 25,000 persons worldwide. USH
is divided into clinical subtypes I, II, or III, based on
severity and progression of vision and hearing loss [2].
Patients with Usher I have congenital deafness and
begin to lose their vision early in life. They also exhibit
difficulty balancing due to vestibular problems. Pa-
tients with Usher II exhibit congenital hearing loss
that is mild-moderate in low tones and moderate to
severe at higher frequencies. They generally have a
normal vestibular system. Patients with Usher III are
not born deaf, but experience a gradual loss of both
their hearing and vision. Usher II is the most common
form of USH, and may account for more than half of
all patients with USH [3]. Such complex clinical
heterogeneity often precludes an accurate clinical
diagnosis. Hearing loss in USH is usually caused by
impairment of inner ear structures such as hair cells,
which transmit sound and motion signals to the brain.
Vision loss results from the degeneration of photore-
ceptors in the retina [4].
Due to the genetic heterogeneity of USH, molecular
diagnosis using traditional Sanger sequencing is quite
laborious and expensive [5, 6]. To date, 12 genes
(CDH23, CEP250, CIB2, CLRN1, DFNB31, GPR98,
HARS, MYO7A, PCDH15, USH1C, USH1G and
USH2A) have been reported to be responsible for Usher
syndrome and three additional loci have been mapped.
USH2A, the major pathogenic gene for Usher II, has 72
exons, the entire region of which is scattered with
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implicated mutations. Next-generation sequencing (NGS)
technology has recently been demonstrated to be superior
than Sanger for screening of hundreds of target genes at a
given time [7]. In this study, we adopted an NGS-based
capture technique to reveal genetic defects in two USH
families and aimed to evaluate this method as a routine
diagnostic tool for USH patients.
Methods
Patient recruitment
This study was performed in accordance with the tenets
of the Declaration of Helsinki and the ethics committee
of Taizhou Central Hospital, and written informedcon-
sent was obtained from all study subjects. Two unrelated
Chinese families, including two affected and four un-
affected individuals, were enrolled. Clinical diagnosis of
Usher syndrome was based on examination of audiologic
function, visual acuity, fundus photography and optical
coherence tomography (OCT). Typical initial symptoms
of USH include hearing loss, vision acuity impairment,
night blindness, and bone spicule-like pigmentation and
attenuation of retinal vessels in fundus.
Sample preparation
Peripheral blood was collected from all subjects and
used for DNA extraction using a kit (TIANGEN,
Beijing) according to the manufacturer’s instructions.
DNA yield was quantified with Nanodrop 2000 (Ther-
mal Fisher Scientific, DE).
Targeted gene capture and sequencing
A solution-based sequence capture custom enrichment
kit was used (GenCap, MyGenostics, Beijing), including
199 disease genes [8]. A minimum of 3 ug DNA was
extracted per proband, and fragmented into 200–300 bp
DNA libraries according to the manufacturer’s protocol.
After end-repair and adapter ligation, target libraries
were hybridized with the panel and enriched using the
Illumina Exome Enrichment protocol. Purified and
enriched libraries were then sequenced using an Illu-
mina HiSeq 2000 Sequencer.
Bioinformatics analysis
After HiSeq 2000 re-sequencing, raw sequencing reads
were first filtered by the Solexa QA package [9] and then
by the cutadapt program (https://pypi.python.org/pypi/
cutadapt). High quality reads were aligned to the reference
genome sequence (hg19) by using Burrows-Wheeler
Aligner and duplications were removed by using Sequence
Alignment/Map tools [10]. Only unique aligned reads
were kept for further analysis. Single-nucleotide variants
(SNVs) and insertions or deletions (InDels) were identified
by GATK software [11], and filtered to eliminate low
quality SNVs or those with strand bias or proximity to
InDels. Remaining variants were functionally annotated
across the genome by ANNOVAR. The pathogenicity of
nonsynonymous variants was then evaluated by four
algorithms, PolyPhen2, SIFT, PANTHER and Pmut, as de-
scribed previously [12].
Expanded validation
DNA samples of the parents of two probands were
used to validate all likely pathogenic variants by using
conventional Sanger sequencing, and to perform fa-
milial segregation analyses whenever possible. Purified
PCR products were cycle-sequenced on an ABI 3500
Genetic Analyzer (Applied Biosystems, CA). The re-
sults of Sanger sequencing were analyzed by Mutation
Surveyor (Softgenetics, PA).
Fig. 1 Pedigrees of Usher syndrome in this study. Closed symbols represent affected patients and open symbols indicate unaffected subjects. The
bar over the symbol indicates subjects examined in this study
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Results
Clinical findings
The two families enrolled in this study had USH spor-
adic cases, and two individuals (F1-I-1, F1-I-2) in family
F1 were consanguineous (Fig. 1). The on-set age of
both probands are about 15 years old. In family F1, the
proband (F1-II-1) was 50 years old and suffered night
blindness since adolescence. His visual deterioration
had been progressive and at the time of the study he
was nearly completely blind. He had no vestibular sys-
tem problems. Analysis of pure tone audiogram testing
showed bilateral moderate to severe hearing loss, mod-
erate at low sound frequencies sloping to severe at
higher tested frequencies. Tympanometry examination
demonstrated the normal functions of middle ear and
eardrum. Upon ophthalmologic examination, fundus
photography showed significant bone-spicule pigmenta-
tion in the retinal periphery, attenuated retinal arteries
and waxy pallor of the optic nerve, all typical signs of
retinitis pigmentosa. Results of the OCT test clearly
displayed extremely thin and disorganized inner and
outer photoreceptor segments (Fig. 2). Collectively, this
clinical evidence suggested a diagnosis of Usher II for
this proband. The patient, F2-II-6 from family F2 was
only 20 years old and exhibited symptoms similar to
that of proband F1-II-1 (data not shown). However, the
severity of his symptoms was relatively mild, likely due
to his younger age.
Fig. 2 Clinical examination. a Pure tone audiogram showed bilateral downward-sloping moderate to severe hearing loss in one patient with
Usher syndrome (F1-II-1); b Tympanometry examination demonstrated the normal functions of middle ear and eardrum in the F1-II-1 proband;
c Fundoscopy of the F1-II-1 patient revealed symptoms typical of retinitis pigmentosa. d OCT of the F1-II-1 patient showed that retinal thickness
was diminished
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Candidate mutations identified by targeted exome
sequencing
We performed targeted exome sequencing of two pro-
band samples from the USH families. The average
sequencing depths and coverage of the target regions
were 300 reads and 98.0 %, respectively. The coverage
of targeted exons for >10 reads was 90.7 % and >20
reads was 81.6 %. After processing of raw data through
the BWA program, variants were called and annotated
using GATK. We identified numerous non-synonymous
variants by the GATK program. Any variants that were
reported in the HapMap 28 and the SNP release of the
1000 Genome Project with a MAF > 0.05 were removed.
To evaluate the pathogenicity of the variants, we used
bioinformatics tools to analyze potential impacts on the
function or structure of the encoded proteins. By employ-
ing this stepwise analyses approach, we obtained a list of
candidate mutations for the two probands. Finally, there
were only one homozygous and two heterozygous variants
in USH2A in these two pedigrees, respectively.
Expanded familial validation and Sanger sequencing
confirmation
Results from targeted exome sequencing of samples from
the two probands indicated that they probably had defects
in the USH2A gene. To validate the sequencing results, we
used Sanger sequencing to screen the same mutation sites
in their parents’ DNA. In family F1, we confirmed a hetero-
zygous frameshift mutation (c.4382delA, p.T1462Lfs*2) in
exon 20 of USH2A. In family F2, the unaffected father was
found to have a heterozygous splice site mutation (IVS47 +
1G >A) in intron 48 of USH2A and the unaffected mother
had a novel heterozygous mutation (c.13156A >T) in exon
63 of USH2A. The affected proband, F2-II-6, harbored both
compound heterozygous USH2A mutations (IVS47 + 1G >
A, c.13156A >T) from his parents (Fig. 3).
Analysis of USH2A mutations
The frameshift mutation (c.4382delA, p.T1462Lfs*2) and
the splicing site mutation (IVS47 + 1G > A) found here
has been previously reported in a previous study [8].
The missense variant (c.13156A >T) has not been reported
in the 1000 Genomes database or in any other single
nucleotide polymorphism database. This mutation caused
substitution of phenylalanine for isoleucine at amino acid
position 4386 and was speculated by prediction software to
effect protein functions. In this study, the pathogenicity of
missense was then evaluated by four algorithms, Poly-
Phen2, SIFT, PANTHER and Pmut. All these four algo-
rithms showed the p.I4386F was damaging. It is located in
a highly conserved domain of USH2A, when compared to
other species (Fig. 3). In summary, we successfully identi-
fied causative mutations in two USH families, by combining
Sanger sequencing and co-segregation analysis.
Discussion
Usher syndrome (USH) is the most common cause of
hereditary deafness–blindness of humans. The typical
symptoms are hearing loss and visual dysfunction, with
differing severities in each subtype [13, 14]. Clinical and
genetic heterogeneity of USH makes it difficult to accur-
ately diagnose this disease at a molecular level by con-
ventional direct sequencing. Targeted exome sequencing
is an efficient and low-cost technique for sequencing
hundreds of potential target genes at one time. In this
study, we employed a comprehensive strategy to screen
USH patients for mutation in large group of target genes
responsible for inherited retinal degeneration. We per-
formed target exome sequencing on two probands and
successfully identified causative mutations by combining
familiar validation and co-segregation analyses.
In these two Chinese USH families, mutations in the
USH2A gene were identified to be possibly disease-
Fig. 3 Chromatography and conservation analyses of the mutations. a Sanger sequencing validated mutations harbored by the two probands. b
Amino acid sequence alignments of the areas of novel mutation, in various species
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causing. The missense heterozygous SNV (c.13156A >
T) was a novel mutation located in a highly conserved
region in USH2A. The protein encoded by the USH2A
gene, usherin, is critical for proper development of the
inner ear and retina, which helps explain the incidence
of disease-associated hearing and vision loss. Our find-
ings expanded the spectrum of known USH2A muta-
tions and reflected the significant implication of
USH2A in Usher syndrome (Table 1).
Conclusions
The technology we employed in this study will increase
the accuracy of efficiency by which patients with retinal
dystrophy such as USH, and retinitis pigmentosa receive
diagnosis and prognosis. For those patients and their
family members who are at high risk of disease, an accur-
ate and timely clinical diagnosis can help them obtain
personalized therapy and professional advice on concerns
relating to marriage and procreation.
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Table 1 Identified mutations in USH2A gene
Family Proband Mutation Type Amino Acid Reference
F1 II-1 c.4384delA Homo p.T1462Lfs*2 Reported
F2 II-3 IVS47 + 1G > A Hetero Splice site Reported
F2 II-3 c.13156A > T Hetero p.I4386F Novel
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